Effect of 5-azacytidine and galectin-1 of growth and differentiation of the human b lymphoma cell line bl36

被引：35

作者：

Poirier F. ^{[1
]}

Bourin P. ^{[2
]}

Bladier D. ^{[1
,3
]}

Joubert-Caron R. ^{[1
]}

Caron M. ^{[1
,3
]}

机构：

[1] Biochimie Proteines et Proteomique, U.F.R. SMBH, Université Paris 13, F-93017 Bobigny Cedex

[2] Laboratoire d'Immunologie Cellulaire, Ctr. Transfusion Sanguine des Armees

[3] Laboratoire Central de Biochimie, Hôpital Avicenne

来源：

Cancer Cell International | / 1卷 / 1期

关键词：

Propidium Iodide; BL36 Cell; Gal1 Expression; Plasmacytic Differentiation; AzaC Treatment;

D O I：

10.1186/1475-2867-1-2

中图分类号：

学科分类号：

摘要：

Background: 5-AzaCytidine (AzaC) is a DNA demethylating drugs that has been shown to inhibit cell growth and to induce apoptosis in certain cancer cells. Induced expression of the galectin1 (Gal1) protein, a galactoside-binding protein distributed widely in immune cells, has been described in cultured hepatoma-derived cells treated with AzaC and this event may have a role in the effect of the drug. According to this hypothesis, we investigated the effect of AzaC and Gal1 on human lymphoid B cells phenotype. Methods: The effect of AzaC and Gal1 on cell growth and phenotype was determined on the Burkitt lymphoma cell line BL36. An immunocytochemical analysis for detection of Gal1 protein expression was performed in AzaC-treated cells. To investigate the direct effects of Gal1, recombinant Gal1 was added to cells. Results: Treatment of lymphoid B cells with AzaC results in: i) a decrease in cell growth with an arrest of the cell cycle at G0/G1 phase, ii) phenotypic changes consistent with a differentiated phenotype, and iii) the expression of p16, a tumor-suppressor gene whose expression was dependent of its promoter demethylation, and of Gal1. A targeting of Gal 1 to the plasma membrane follows its cytosolic expression. To determine which of the effects of AzaC might be secondary to the induction of Gal1, recombinant Gal1 was added to BL36 cells. Treated cells displayed growth inhibition and phenotypic changes consistent with a commitment toward differentiation. Conclusions: Altered cell growth and expression of the cell surface plasma cell antigen, CD138 are detectable in BL36 cells treated by AzaC as well as by Gal1. It seems that AzaC-induced Gal1 expression and consequent binding of Gal1 on its cell membrane receptor may be, in part, involved in AzaC-induced plasmacytic differentiation. © 2001 : licensee BioMed Central Ltd.

引用

页数：12

共 65 条

[1]

Schmutte C., Jones P.A., Involvement of DNA methylation in human carcinogenesis, Biol. Chem., 379, pp. 377-388, (1998)

[2]

Momparler R.L., Bovenzi V., DNA methylation and cancer, J. Cell Physiol., 183, pp. 145-154, (2000)

[3]

Murakami T., Li X., Gong J., Bhatiah U., Traganos F., Darzynkiewicz Z., Induction of apoptosis by 5-azacytidine: Drug concentration-dependent differences in cell cycle specificity, Cancer Res., 55, pp. 3093-3098, (1995)

[4]

Wang X.M., Wang X., Li J., Evers B.M., Effects of 5-azacytidine and butyrate on differentiation and apoptosis of hepatic cancer cell lines, Ann. Surg., 227, pp. 922-931, (1998)

[5]

Masucci M.G., Contreras-Salazar B., Ragnar E., Falk K., Minarovits J., Ernberd I., Klein G., 5-Azacytidine up regulates the expression of EBV nuclear antigen 2 (EBNA2) through ENBNA6 and latent membrane protein in Burkitt's lymphoma line rael, J. Virol., 63, pp. 3135-3141, (1989)

[6]

Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P., Bennett W.P., Forrester K., Gerwin B., Serrano M., Beach D.H., Et al., Mutations and altered expression of pl6INK4 in human cancer, Proc. Natl. Acad. Sci. USA, 91, pp. 11045-11049, (1994)

[7]

Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D., CpG island methylation is associated with transcriptional silencing of the tumour suppressor pl6/ CDKN2/MTS1 in human cancers, Nat. Med., 1, pp. 686-692, (1995)

[8]

Singal R., Ginder G.D., DNA methylation, Blood, 93, pp. 4059-4070, (1999)

[9]

Lubbert M., DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndroms, hemoglobinopathies: Clinical results and possible mechanisms of action, Curr. Top. Microbiol. Immunol., 249, pp. 135-164, (2000)

[10]

Hadari Y.R., Arbel-Goren R., Levy Y., Amsterdam A., Alon R., Zakut R., Zick Y., Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis, J. Cell Sci., 113, pp. 2385-2397, (2000)

← 1 2 3 4 5 6 7 →